Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
ORTHO-CEPT is an oral contraceptive tablet approved in 1992 by Johnson & Johnson. The product is a small-molecule hormonal contraceptive indicated for pregnancy prevention in women of reproductive age. It represents a mature, established therapy in the oral contraceptive class.
Product faces moderate competitive pressure (30%) with approaching loss-of-exclusivity; career opportunities center on managed decline, generic transition support, and retention of market share through differentiation strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO-CEPT offers stability in a mature product but limited growth runway; career advancement depends on successfully managing the LOE transition and executing generic defense strategies. Roles are primarily commercial and tactical rather than innovative, suited for professionals focused on operational excellence over new product launches.
Worked on ORTHO-CEPT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.